BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...Adagene’s offering are Goldman Sachs Asia, Morgan Stanley, Jefferies and China Renaissance. NexImmune’s underwriters are Barclays...
BioCentury | Nov 11, 2020
Politics, Policy & Law

Biden-Harris HHS transition team includes FDA, public health expertise

The Biden-Harris transition team Tuesday announced membership in teams that will smooth the path for the incoming administration at federal agencies, including HHS. The 30-member HHS agency review team will make recommendations that will set...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

Taysha joins IPO queue four months after spinoutTaysha Gene Therapies Inc. proposed to raise up to $100 million in a NASDAQ IPO. Founded in partnership with the University of Texas Southwestern Medical Center, the company...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp. and served as chairman and CEO of Pfizer Inc. (NYSE:PFE) in 2006-10. Mission Therapeutics Ltd. promoted Paul...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...business development. She was managing director and chair of the global life sciences group at Barclays...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...to 9.25 million shares from 6.25 million; its proposed range was $15-$17. J.P. Morgan, Jefferies, Barclays...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...proposed the offering. The company added $1.82 (22%) to $10.09 on Thursday. Underwriters are Cowen, Barclays...
BioCentury | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

...$70 million and $69 million, respectively. Vir’s underwriters are Goldman Sachs, J.P. Morgan, Cowen and Barclays...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...at a postmoney valuation of $2.3 billion. Underwriters are Goldman Sachs, J.P. Morgan, Cowen and Barclays...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays...
Items per page:
1 - 10 of 572
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...Adagene’s offering are Goldman Sachs Asia, Morgan Stanley, Jefferies and China Renaissance. NexImmune’s underwriters are Barclays...
BioCentury | Nov 11, 2020
Politics, Policy & Law

Biden-Harris HHS transition team includes FDA, public health expertise

The Biden-Harris transition team Tuesday announced membership in teams that will smooth the path for the incoming administration at federal agencies, including HHS. The 30-member HHS agency review team will make recommendations that will set...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

Taysha joins IPO queue four months after spinoutTaysha Gene Therapies Inc. proposed to raise up to $100 million in a NASDAQ IPO. Founded in partnership with the University of Texas Southwestern Medical Center, the company...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp. and served as chairman and CEO of Pfizer Inc. (NYSE:PFE) in 2006-10. Mission Therapeutics Ltd. promoted Paul...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...business development. She was managing director and chair of the global life sciences group at Barclays...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...to 9.25 million shares from 6.25 million; its proposed range was $15-$17. J.P. Morgan, Jefferies, Barclays...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...proposed the offering. The company added $1.82 (22%) to $10.09 on Thursday. Underwriters are Cowen, Barclays...
BioCentury | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

...$70 million and $69 million, respectively. Vir’s underwriters are Goldman Sachs, J.P. Morgan, Cowen and Barclays...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...at a postmoney valuation of $2.3 billion. Underwriters are Goldman Sachs, J.P. Morgan, Cowen and Barclays...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays...
Items per page:
1 - 10 of 572